Invention Grant
- Patent Title: Fusions of antibodies to CD38 and attenuated interferon alpha
-
Application No.: US14262841Application Date: 2014-04-28
-
Publication No.: US09611322B2Publication Date: 2017-04-04
- Inventor: David S. Wilson, Jr. , Sarah L. Pogue , Glen E. Mikesell , Tetsuya Taura , Wouter Korver , Anthony G. Doyle , Adam Clarke , Matthew Pollard , Stephen Tran , Jack Tzu Chiao Lin
- Applicant: Teva Pharmaceuticals Australia Pty Ltd
- Applicant Address: AU Macquarie Park, NSW
- Assignee: Teva Pharmaceuticals Australia Pty Ltd
- Current Assignee: Teva Pharmaceuticals Australia Pty Ltd
- Current Assignee Address: AU Macquarie Park, NSW
- Agency: Stradley Ronon Stevens & Young, LLP
- Priority: AU2011904502 20111028
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/46 ; C07K14/56 ; C07K14/54 ; C07K14/565 ; C07K14/57 ; C07K16/10
Abstract:
The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
Public/Granted literature
- US20140248238A1 POLYPEPTIDE CONSTRUCTS AND USES THEREOF Public/Granted day:2014-09-04
Information query
